Babson Diagnostics Named Fierce MedTech “Fierce 15" Company

The conventional diagnostic blood testing experience has not changed notably since it was created 70 years ago. Babson Diagnostics is the first company to present a true alternative to venipuncture, with novel technology designed to use small fingertip samples less than one-tenth the volume without sacrificing quality, accuracy, or menu breadth. Babson will deploy its proprietary technological ecosystem at accessible retail locations such as pharmacy counters throughout the country, giving customers the benefit of longer hours of operation, low out-of-pocket costs, and a more humane experience.

“Babson Diagnostics is honored to be among this select group of Fierce Medtech innovators,” said David Stein, Ph.D., Babson’s CEO. “COVID-19 reinforced that there is an urgent need to shift diagnostic blood testing from centralized collection sites to decentralized, accessible locations. We are proud that Fierce Medtech recognized Babson for our progress toward improving customer health by expanding access to care.”

Babson has partnered with world-leading medical technology companies BD (Becton, Dickinson and Company) and Siemens Healthineers in a shared mission of expanding access to diagnostic blood testing and supporting earlier identification of risks for chronic and non-communicable diseases.

To demonstrate the accuracy of its novel technology, Babson recently conducted the pivotal clinical study “Dandelion Alpha,” which compared its sample collection, sample handling, and analysis technology to conventional blood testing technology in a retail setting and produced strongly correlated test results.

“Initial clinical data reinforces the potential to test a full set of routine diagnostic blood panels from a small capillary sample collected in a convenient retail setting and produce accurate, diagnostic-quality results,” says Stein. “By improving the customer experience of blood testing and removing barriers to access, we hope to help customers engage with their health and achieve their personal health goals.”

The Fierce 15 celebrates the spirit of being “fierce” — championing innovation and creativity, even in the face of intense competition. This is Fierce Medtech’s 9th annual Fierce 15 selection. This year’s full list of winners can be viewed online at https://www.fiercebiotech.com/special-report/fierce-medtech-s-2020-fierce-15.

“Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic,” said Conor Hale, associate editor of Fierce Medtech.

An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day’s top stories. Every year, Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors including the strength of its technology, partnerships, venture backers, and a competitive market position.

About Fierce MedTech
Fierce Medtech keeps biopharma executives, device developers, engineers and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day’s top stories.

About Babson Diagnostics
Babson Diagnostics aims to democratize diagnostic blood testing by making it easier, faster and more pleasant for customers to routinely monitor and improve their health. Babson’s proprietary technological ecosystem is designed to deliver accurate diagnostic results with a more human experience. Based in Austin, Texas, its vision for diagnostic blood testing — built on accuracy, convenience, and accessibility — combines transformative diagnostic technology with a customer-first, retail-centric business model that aims to improve customer health and experience. Prior to commercialization, Babson Diagnostics is working with retail pharmacies to validate its technology by conducting clinical studies intended for peer-reviewed publication. For more information on Babson Diagnostics, please visit www.babsondx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005309/en/